Pancreatic cancer pancreatic cancer, pancreatic ductal carcinoma, invasive pancreatic ductal carcinoma
Conditions
Interventions
[Administration of S-1]
1.The initial dose of S-1 is calculated from the body surface area according to the package insert as follows.
2.S-1 is orally administered twice a day after breakfast and afte
neoadjuvant chemotherapy, carbon ion radiotherapy, surgical resection, conversion surgery, adjuvant chemotherapy
Sponsors
Shirabe Ken
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Histologically or cytologically diagnosed adenocarcinoma, or clinically diagnosed pancreatic cancer by both imaging and tumor markers 2) No distant metastasis was observed at the time of registration, and the primary tumor was diagnosed as borderline resectable (BR-A) or unresectable locally advanced (UR-LA) (Pancreatic cancer treatment regulations 7th edition ) 3) Patients aged 20 years or older at enrollment 4) Patients with PS 0-1 5) CTCAE grade 2 if induction chemotherapy (BR: 2 or more courses, UR-LA: 4 or more courses) is performed for the primary disease and there is no obvious tumor progression after the start of treatment, or if serious adverse events are observed recovering to 6) Patients with preserved major organ functions (bone marrow, liver, kidney, lung, etc.) (a) White blood cells: 12,000 /mm3 (b) Neutrophils: more than or equal to 1,500 /mm3 (c) Hemoglobin level: more than or equal to 9.0 g/dL (d) Platelets: more than or equal to 100,000 /mm3 (e) Total bilirubin: less than 2.0 mg/dL (less than 3.0 mg/dL in cases of reduced yellowness) (f) Creatinine: 1.5 mg/dl or less (g) AST and ALT: 2.5 times facility standard upper limit or less 7) Patients who have given their consent to participate in this study
Exclusion criteria
Exclusion criteria: 1) Patients with previous treatment (radiation therapy, chemotherapy, immunotherapy, etc.) other than the prescribed chemotherapy for the primary disease 2) Patients with distant metastases 3) Patients after primary tumor resection 4) Patients contraindicated for administration of S-1 5) Patients with obvious infection or inflammation at the time of study enrollment (such as patients with a fever of 38.0 degree or higher) 6) Patients with serious complications (requiring hospitalization) (cardiac disease, intestinal paralysis, intestinal obstruction, interstitial pneumonia or pulmonary fibrosis, difficult-to-control diabetes, renal failure, liver cirrhosis, etc.) 7) Patients with refractory ascites or pleural effusion 8) Patients with gastrointestinal fresh bleeding requiring repeated transfusions 9) Patients with diarrhea (more than 4 times a day or watery stools) 10) Patients with active double cancer at enrollment 11) Pregnant women, breastfeeding women, and women with the possibility (or intention) of becoming pregnant 12) Patients with radiation hypersensitivity at the time of enrollment 13) Patients who are considered difficult to obtain effective informed consent 14) In addition, patients who are judged to be inappropriate by the doctor's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resection rate, R0 resection rate, postoperative complication | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, recurrence-free survival, changes in ctDNA levels | — |
Contacts
Public ContactKenichiro Araki
Gunma University Hospital
Outcome results
None listed